The Japanese drug maker Otsuka has been approved to purchase the assets of bankrupt smart pill maker Proteus Digital Health for $15 million — capping off a spectacular fall for Proteus, which raised close to $500 million and soared to a valuation of $1.5 billion on the promise that its sensor technology could revolutionize how medications are taken and tracked.

The sale, approved on Wednesday by a federal bankruptcy court judge in Delaware after a three-day hearing, overcame the fierce objections of a group of Proteus investors that included the pharma giant Novartis. Those investors opposed Otsuka’s purchase of Proteus because they thought Otsuka, a longtime Proteus investor and partner, was an insider and that Proteus’s assets could go for a higher price had they been divided up and left up for sale for a longer period.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy